Owen McCarty: The Potential Benefit of Targeting FXI in Sepsis
Owen McCarty, Professor and Chair at Oregon Health and Science University, shared a post on LinkedIn:
“Our recent preclinical work highlighting the potential benefit of targeting FXI in sepsis. Led by Robert Silasi and Ravi Shankar Keshari, Ph.D with Aleksandr Shamanaev, Samantha (Sami) Moellmer, Cristina Puy Garcia, PhD, Joseph Shatzel, and Florea Lupu.”
Title: Protective effects of factor XI inhibition by abelacimab in a baboon model of live Staphylococcus aureus sepsis
Authors: Robert Silasi, Ravi S. Keshari, Tomohiro Abe, Stephanie D. Byrum, Girija Regmi, Cristina Lupu, Constantin Georgescu, Joe H. Simmons, Aleksandr Shamanaev, Samantha A. Moellmer, Cristina Puy, Joseph J. Shatzel, Dennis Province, Rick D. Edmondson, Samuel G. Mackintosh, Nathan L. Avaritt, Dan Bloomfield, David Gailani, Alan J. Tackett, Owen J.T. McCarty, Florea Lupu
Read full artile here.
Stay updated with Hemostasis Today.
-
Nov 27, 2025, 16:00Nathan Connell on WFH AI Summaries from the Global Forum
-
Nov 27, 2025, 15:49Piotr Czempik: Rethinking Coagulation in Acute Liver Dysfunction
-
Nov 27, 2025, 15:35Overwhelmed? A Leader’s Guide from Mark Crowther to Getting Back on Track
-
Nov 27, 2025, 15:10Wolfgang Miesbach’s Top 10 Picks for TTP and Thrombosis from ASH 2025
-
Nov 27, 2025, 14:24ICCBBA’s Executive Director Eoin McGrath Chairs a Dynamic Session on AI, Innovation and Informatics in Transfusion Medicine
-
Nov 27, 2025, 13:26Wolfgang Miesbach’s Top 10 Picks for Bleeding Disorders from ASH 2025
-
Nov 27, 2025, 11:19Priya Prasad Presents a Case of Severe Hypotensive Transfusion Reaction
-
Nov 27, 2025, 04:07Eugene Tang Presents Highlights from UK Stroke Forum 2025
-
Nov 27, 2025, 03:47Michael Makris: I Believe the Time Has Come to Consider Emicizumab Up Front in Persons with Acquired Hemophilia